NOBEN ® [Idebenon]

Dosage and administration

The normal dose is 60 - 90 mg 2-3 times per day. The duration of a course of treatment can vary from 1 to 2 months. Depending on the symptoms, the course can be taken 2-3 times per year.

Side effects

Side effects include allergic reactions (itchy skin), headaches, difficulty falling asleep and dyspepsia.

Overdose

An increase in potential side effects.

Note: Anecdotal reports in Russia show that Noben is pretty effective as a nootropic agent but the effect may vary depending on the individual's brain chemistry.

Country of Manufacture: Russia

4 Weeks Course is 90 pills x 30mg - Save with the volume discount!

Already in February 2007, Idebenon has been described as an orphan drug for the treatment of Leber's hereditary optic neuropathy (LHON). In 2016, the European commission  approved the drug for the treatment of this condition. In the US, the drug has been given "fast track" by FDA as a potential treatment for Duchenne Muscular Dystrophy (DMD

In the same time, in Russia Idebenon is being used for treatment of MELAS (mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes), Leber's hereditary optic neuropathy (LHON), Duchenne muscular dystrophy (Catena) and some other conditions. 

A number of researchers recommend Idebenon therapy for the treatment of various neurological disorders due its nootropic pharmacology.

Indeed, as a structural analogue of CoQ10, the drug was shown to improve cerebral blood flow and oxygen delivery to human brain. It improves metabolic processes; in particular, it increases synthesis of glucose and adenosine triphosphate (ATP) and supports lactate elimination. Also, Idebenon slows down the process of lipid peroxidation and protects membranes of neurones and mitochondria from damage.   

The drug is produced by Binnopharm in a large pharmaceutical factory located in the city of Zelenograd.

  1. Gillis et al (1994) Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders https://www.ncbi.nlm.nih.gov/pubmed/7981485
  2. H Gutzmann, D Hadler (1998) Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study https://www.ncbi.nlm.nih.gov/pubmed/9850939
  3. Gutzmann et al (2002) Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study https://www.ncbi.nlm.nih.gov/pubmed/11819153
  4. Hausse et al (2002) Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia https://www.ncbi.nlm.nih.gov/pubmed/11907009
  5. Thai et al (2003) Idebenone treatment fails to slow cognitive decline in Alzheimer's disease https://www.ncbi.nlm.nih.gov/pubmed/14663031
  6. McDaniel et al (2005) Clinical efficacy assessment in photodamaged skin of 0.5% and 1.0% idebenone https://www.ncbi.nlm.nih.gov/pubmed/17129261
  7. Di Prospero et al (2007) Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial https://www.ncbi.nlm.nih.gov/pubmed/17826341
  8. Schulz et al (2009) Clinical experience with high-dose idebenone in Friedreich ataxia https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4277883/
  9. K Voronkova, M Meleshkov (2009) Use of Noben (idebenone) in the treatment of dementia and memory impairments without dementia https://www.ncbi.nlm.nih.gov/pubmed/19430983
  10. Klopstock et al (2011) A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3170530/
  11. Gerhardt et al (2011) Idebenone and Resveratrol Extend Lifespan and Improve Motor Function of HtrA2 Knockout Mice https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242749/
  12. Klopstock et al (2013) Persistence of the treatment effect of idebenone in Leber’s hereditary optic neuropathy https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3572931/
  13. S Jaber, B Polster (2015) Idebenone and neuroprotection: antioxidant, pro-oxidant, or electron carrier? https://www.ncbi.nlm.nih.gov/pubmed/25262284
  14. Guan et al (2016) Idebenone Maintains Survival of Mutant Myocilin Cells by Inhibiting Apoptosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989434/
  15. K Lyseng-Williamson (2016) Idebenone: A Review in Leber's Hereditary Optic Neuropathy https://www.ncbi.nlm.nih.gov/pubmed/27071925
  16. Yu-Wai-Man et al (2017) Evaluating the therapeutic potential of idebenone and related quinone analogues in Leber hereditary optic neuropathy https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644719/
  17. Montenegro et al (2018) Idebenone: Novel Strategies to Improve Its Systemic and Local Efficacy https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5853719/
  18. Tiefenbach et al (2018) Idebenone and coenzyme Q10 are novel PPARα/γ ligands, with potential for treatment of fatty liver diseases https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6177011/


Type: Nootropics




CUSTOMERS WHO BOUGHT THIS PRODUCT ALSO BOUGHT